On October 18, 2026, Zhejiang Tianyuan Biotechnology Co., Ltd. officially established a school-enterprise partnership with Zhejiang Pharmaceutical Vocational University. The two parties will fully leverage their respective strengths in scientific research, talent, and industry, carrying out in-depth cooperation in three key areas: IND application for cell-based drugs, GMP laboratory upgrades, and the development of group standards for the Zhejiang Pharmaceutical Association, further promoting the translation of research achievements into industrial applications.

      As a platform-based biopharmaceutical enterprise driven by AI + iPSC technology and focused on the development of drugs for heart failure treatment, Tianyuan Biotechnology has built a full-chain R&D platform covering cell reprogramming, disease model construction, and candidate drug validation, and has continued to make breakthroughs in areas such as iPS-derived cardiomyocytes and organoid research.

      Zhejiang Pharmaceutical Vocational University, the only undergraduate-level vocational university in China's drug administration system, has a solid foundation in pharmaceutical sciences, GMP management, cell therapy technology, drug quality standards, and industry-education integration. This partnership will further create a complementary combination of the university's professional expertise and the enterprise's industrial practice.

From Technology Accumulation to New Drug Development, Entering a New Stage of Growth

      For Tianyuan Biotechnology, the value of this signing lies in the fact that the company's future development strategy is becoming increasingly clear. The company will continue to build on its iPS cell technology platform as the foundation, take innovative drug development as its core growth direction, and further expand a complete R&D chain that extends from basic research and disease modeling to candidate drug screening, preclinical studies, IND application, and industrialization.

      This partnership also means that the company is proactively strengthening key capabilities in professional technology, quality systems, and regulatory application throughout the innovative drug development process, creating more mature conditions for the continued advancement of its R&D pipeline.

      From individual technology breakthroughs to platform capability building, and from accumulated research achievements to innovative drug product development, Tianyuan Biotechnology is gradually shaping a more scalable platform-based biopharmaceutical development model. 。

Looking Ahead: Building Sustainable Innovation Value

      At present, cutting-edge technologies such as cell and gene therapy and regenerative medicine have become a major focus of the global biopharmaceutical industry. For enterprises with core technology platforms and sustained R&D capabilities, how to further translate technological advantages into innovative products with clinical and industrial value is a key factor determining long-term competitiveness.

      This partnership with Zhejiang Pharmaceutical Vocational University marks an important milestone in the advancement of Tianyuan Biotechnology's new drug development strategy. As its R&D system, quality system, and achievement transformation capabilities continue to improve, the company is expected to further unlock the industrial value of its iPS cell technology platform, building a sustained capability to transform from core technologies to innovative products, and from R&D capability to industrial value.

      With scientific research as the foundation and innovation as the driving force, Tianyuan Biotechnology will continue to deepen its focus on iPS cell and cell-based drug development, accelerate the transformation of cutting-edge life science technologies into innovative achievements, and steadily advance toward becoming a platform-based biopharmaceutical enterprise with sustained R&D capabilities, core technological competitiveness, and industrialization potential.

      Founded in 2017, Zhejiang Tianyuan Biotechnology Co., Ltd. is a platform-based biopharmaceutical enterprise driven by AI + iPSC technology and dedicated to developing drugs for heart failure treatment. With its iPS seed cell bank, tumor cell bank, and HLA compatibility matching system as cornerstones, the company has built a full-chain R&D platform covering cell reprogramming, disease model construction, and candidate drug validation. Leveraging the policy advantages of Hainan's "Medical Special Zone," the company has opened up the "last mile" of clinical translation; through its regional network of facilities, it has achieved integrated operations spanning collection, preparation, R&D, and application; and with a closed-loop marketing ecosystem, it connects medical institutions, research platforms, and end users.